Improvement of serum lipids concentration in a general population historical cohort. Why?

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

“…If the population mean LDL-C level before treatment is approximately between 3.0 and 3.5 mmol/L, 12 , 13 patients considered to be at very high risk and patients considered to be at very high risk and with recurrent CV events are unlikely to achieve LDL-C levels below 1.4 mmol/L and below 1.0 mmol/L, respectively, without the use of combination therapy. This is analogous to the approach of managing hypertension, where patients are routinely recommended to initiate treatment with combination therapy as a first step.…”